BR112021000796A2 - Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol - Google Patents

Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol

Info

Publication number
BR112021000796A2
BR112021000796A2 BR112021000796A BR112021000796A BR112021000796A2 BR 112021000796 A2 BR112021000796 A2 BR 112021000796A2 BR 112021000796 A BR112021000796 A BR 112021000796A BR 112021000796 A BR112021000796 A BR 112021000796A BR 112021000796 A2 BR112021000796 A2 BR 112021000796A2
Authority
BR
Brazil
Prior art keywords
octahydro
benzo
quinoline
propyl
dioxolo
Prior art date
Application number
BR112021000796A
Other languages
English (en)
Inventor
Dennis Therkelsen Frans
Kåre Søndergaard
Martin Juhl
Fog Jacobsen Mikkel
Gylling Frihed Tobias
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112021000796A2 publication Critical patent/BR112021000796A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol. a presente invenção refere-se a um novo processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6] benzo[1,2-g]quinolina com a fórmula (ib) abaixo, (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol com a fórmula (i) abaixo e sais do mesmo. ambos os compostos são para uso no tratamento de doenças e disfunções neurodegenerativas, tais como a doença de parkinson. a invenção se refere também com novos compostos intermediários do referido processo.
BR112021000796A 2019-05-20 2020-05-19 Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol BR112021000796A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900600 2019-05-20
PCT/EP2020/063913 WO2020234273A1 (en) 2019-05-20 2020-05-19 A process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol

Publications (1)

Publication Number Publication Date
BR112021000796A2 true BR112021000796A2 (pt) 2021-11-30

Family

ID=70857150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000796A BR112021000796A2 (pt) 2019-05-20 2020-05-19 Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol

Country Status (15)

Country Link
US (3) US11168056B2 (pt)
EP (1) EP3972958A1 (pt)
JP (1) JP2022533155A (pt)
KR (1) KR20220009949A (pt)
CN (1) CN113874355A (pt)
AR (1) AR123407A1 (pt)
AU (1) AU2020278810A1 (pt)
BR (1) BR112021000796A2 (pt)
CA (1) CA3140803A1 (pt)
CL (1) CL2021003016A1 (pt)
IL (1) IL288053A (pt)
MX (1) MX2021014016A (pt)
SG (1) SG11202112721WA (pt)
WO (1) WO2020234273A1 (pt)
ZA (1) ZA202109122B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208865A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
DE19575006I2 (de) 1981-10-16 2003-01-09 Novartis Ag 1, 2, 3, 4a, 5, 10, 10a-Octahydrobenzo(g)chinolin-Derivate mit pharmazeutischer Wirkung
PH22782A (en) 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
CA2405419A1 (en) 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
BR0113170A (pt) 2000-08-11 2004-01-06 Purdue Research Foundation Processo para a preparação de dinapsolina
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
ATE365040T1 (de) 2001-08-10 2007-07-15 Purdue Research Foundation Chirales dinapsolin
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
CN1720054A (zh) 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1699450A4 (en) 2003-12-23 2009-11-11 Darpharma Inc Simultaneous administration of dopamine receptor bindings
WO2006012640A2 (en) 2004-07-21 2006-02-02 Darpharma, Inc. Method of administration of dopamine receptor agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
BR112017008198B1 (pt) 2014-10-21 2021-02-09 Abbvie Inc combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
US20190224220A1 (en) 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727979A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP2022533914A (ja) 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
CN113677675A (zh) 2019-05-21 2021-11-19 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease

Also Published As

Publication number Publication date
US11866410B2 (en) 2024-01-09
CN113874355A (zh) 2021-12-31
ZA202109122B (en) 2023-10-25
KR20220009949A (ko) 2022-01-25
US11168056B2 (en) 2021-11-09
CA3140803A1 (en) 2020-11-26
US20200369615A1 (en) 2020-11-26
JP2022533155A (ja) 2022-07-21
AU2020278810A1 (en) 2021-12-16
US20240018107A1 (en) 2024-01-18
CL2021003016A1 (es) 2022-06-24
SG11202112721WA (en) 2021-12-30
IL288053A (en) 2022-01-01
AR123407A1 (es) 2022-11-30
US20220024875A1 (en) 2022-01-27
WO2020234273A1 (en) 2020-11-26
EP3972958A1 (en) 2022-03-30
MX2021014016A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
BR112021000796A2 (pt) Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
ECSP13012892A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
CY1117663T1 (el) Παραγωγα 6,7-διυδρο-πυραζολο[1,5-α]πυραζιν-4-υλαμινης χρησιμα ως αναστολεις β-σεκρετασης (bace)
ECSP066730A (es) Compuestos y procedimientos para uso
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
BR112014012217A2 (pt) derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
UY32574A (es) Antagonistas del receptor cxcr3
BR112014022106A2 (pt) derivados macrocíclicos para o tratamento de doenças
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
CO6362014A2 (es) Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso
BR112014026952A8 (pt) derivados de aminopirimidina pirazol, seus usos, e composição
BR112014011219A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
CL2021002961A1 (es) Un procedimiento para la fabricación de ácido(2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a, 5,10,10a-octahidrobenzo[g]quinolin-6-il)oxi) tetrahidro-2h-piran-2-carboxílico.
MX2021013112A (es) Un procedimiento para la fabricacion de acido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-prop il-1,2,3,4,4a,5,10,10a-octahidrobenzo[g]quinolin-6-il)oxi)tetrahi dro-2h-piran-2-carboxilico e intermedio del mismo.
BR112022003704A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
BR112016022519A8 (pt) cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo